Premium
One‐year follow‐up study of psychotic patients treated with blonanserin: A case series
Author(s) -
Takahashi Sakae,
Suzuki Masahiro,
Uchiyama Makoto
Publication year - 2013
Publication title -
asia‐pacific psychiatry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.654
H-Index - 21
eISSN - 1758-5872
pISSN - 1758-5864
DOI - 10.1111/j.1758-5872.2012.00232.x
Subject(s) - olanzapine , risperidone , schizophrenia (object oriented programming) , antipsychotic , medicine , adverse effect , psychiatry , pediatrics
Blonanserin is a relatively new atypical antipsychotic drug, and has been used in Korea and J apan for 1 and 3 years, respectively. Therefore, the clinical characteristics of blonanserin remain unclear. In this study, to clarify the features of blonanserin, we performed prospective and long‐term comparative investigations of patients treated with blonanserin. Methods We followed 10 psychiatric patients who were switched to blonanserin from other antipsychotics for 1 year (schizophrenia: 8; mental retardation: 2). In the light of quality of life, we focused on adverse effects of patients during the follow‐up. Results I n the long‐term follow‐up, (i) hyperprolactinemia is more frequently in risperidone than in blonanserin; however, it is more often in blonanserin than in olanzapine; and (ii) weight gain is more common in olanzapine than in blonanserin. Discussion We switched to blonanserin from other antipsychotic drugs within the same case, and then followed the case for 1 year. We consider that long‐term observations within the same case lead to obvious comparisons among drugs. On the basis of our findings, we conclude that blonanserin may be useful for the maintenance treatment of schizophrenia without inducing hyperprolactinemia and weight gain.